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METASTATIC SARCOMA TO 
THE LUNG OR DIFFUSE 
BRONCHIOLOALVEOLAR 
CARCINOMA 
Eight patients with metastatic sarcoma to the lung (n = 4) or diffuse 
bronchioloalveolar carcinoma of the lung (n = 4) underwent isolated lung 
perfusion with chemotherapy in a pilot study. Ages ranged from 18 to 60 years 
and half were female. The left lung was perfused in three patients (single lung 
perfusion) and both lungs in five patients (total lung perfusion). Perfusions 
ranged from 45 to 60 minutes at ambient or normothermic temperatures. One 
patient received perfusion at moderate hyperthermia (40 ° C). Escalating doses 
of doxorubicin (1 to 10 pg/ml perfusate) was used in six patients, whereas two 
received cisplatin (14 and 20 pg/ml perfusate). There were two major compli- 
cations and no objective responses. The isolated perfusion systems gave 
excellent separation between systemic and pulmonary circulations with zero to 
15% of the measured peak drug concentration of the pulmonary perfusate 
detected in the systemic irculation. Drug concentrations in normal lung and 
tumor generally increased with higher drug dosages and drug was detectable in 
mediastinal lymph nodes of three out of four patients in whom sampling was 
done. Isolated lung perfusion with chemotherapy can be done safely in patients 
with lung malignancies and evidence suggests that higher drug dosages should 
be well tolerated. (J THORAC CARDIOVASC SURG 1995;110:368-73) 
Michael R. Johnston, MD, a Rodney F. Minchen, PhD, b and 
Christopher A. Dawson, PhD, c Toronto, Ontario, Canada, 
Nedlands, Western Australia, and Milwaukee, Wis. 
R egional perfusion and isolated organ perfusion have been investigated as potential methods to 
deliver high doses of anticancer agents to tumors 
while limiting the systemic toxicities of the drug. 
Dose-limiting toxicities develop in many patients 
undergoing systemic hemotherapy before they have 
beneficial effects of the therapy. Perfusion may 
provide more efficacious treatment in those with 
localized, but unresectable, disease. We have previ- 
ously described surgical techniques for isolated per- 
fusion of a single lung or both lungs simultane- 
ously.i, 2 We have also documented both the acute 
and chronic physiologic onsequences of lung per- 
fusion. In separate studies we provided detailed 
pharmacologic and toxicologic data on the effects of 
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doxorubicin (Adriamycin) when administered by 
lung perfusion 3-5 and have shown that hyperthermic 
perfusion is exceptionally well tolerated by the nor- 
mal lung. 6' 7 This study documents our experience in 
a human trial of lung perfusion. We describe a 
unique series of eight patients with locally advanced 
cancers limited to the lung who underwent isolated 
lung perfusion with either doxorubicin or cisplatin 
added to the lung perfusate. 
Methods 
From 1982 to 1991 eight patients with locally advanced 
cancers limited to the lung were entered into a pilot trial 
of lung perfusion with chemotherapy. Patients' ages 
ranged from 18 to 60 years and there were equal numbers 
of male and female patients. The initial three patients, all 
with metastatic soft tissue sarcomas, underwent single 
lung pelfusion with doxorubicin at the Surgery Branch of 
the National Cancer Institute, Bethesda, Md. The subse- 
quent five perfusions were done at the University of Colo- 
rado Health Sciences Center in Denver. Four patients had 
primary lung cancer and one had metastatic sarcoma. In all 
five patients total ung perfusion was done during cardiopul- 
monary bypass, three with doxolubicin and two with cispla- 
tin. Moderate hyperthermia was used in one patient. The 
study protocol was approved by the Institutional Review 
Board of both institutions and written informed consent was 
obtained from each patient. Demographic data on the eight 
patients are shown in Table I. 
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Table I. Demographic data and forced expiratory 
volume in 1 second in patients undergoing lung 
perfusion 
Patient Age FEVz (% 
No. (yr) Sex Cell type predicted) 1 Single 
1 18 M Fibrosarcoma 2.71 (60) 2 Single 
2 38 M Neurofibrosarcoma 3 Single 
3 32 F Stromal sarcoma 2.21 (73) 4 Total 
4 53 F BAC 1.07 (41) 5 Total 
5 58 F BAC 2.47 (95) 6 Total 
6 60 M BAC 2.15 (81) 7 Total 
7 58 M BAC 2.46 (66) 8 Total 
8 38 F Chondrosarcoma 2.57 (91) PA, Pulmonary artery. 
FEV1, Forced expiratory volume in 1 second; M, male; F, female; BAC, 
bronchioloalveolar carcinoma. 
Lung perfusion techniques in the canine model have 
been previously described in detail. 1' 2 The procedures in 
human beings are not substantially different, but are 
generally easier to do because of larger anatomic struc- 
tures. The following brief description of the precedures 
gives pertinent differences between canine and human 
techniques. Specific perfusion parameters for the eight 
patients are listed in Table II. 
Single lung perfusion. All of the canine and human 
perfusions have been done on the left lung because of 
easier arterial and venous cannulation. The comparatively 
longer segment of left pulmonary artery available for 
securing the arterial cannula nd the convenience ofusing 
the left atrial appendage for venous cannulation are 
important considerations in the dog, but probably not as 
crucial in human beings. Pulmonary artery pressure and 
perfusate temperature are best monitored by a therm- 
istor-tipped pulmonary artery catheter. It is important to 
ensure that the perfusion parameters are stable and that 
the perfusate 'volume in the reservoir is relatively constant 
before drug is added to the perfusate. Once drug is added 
to the perfusate, it is mixed within the extracorporeal 
circuit for at least 5 minutes before lung perfusion is 
recommenced. To facilitate this mixing, a shunt line, or 
"ductus," is included in the tubing circuit and placed as 
close to the arterial and venous cannulas as feasible. This 
allows for mixing of the drug in the largest volume of 
perfusate possible. 
Total lung perfusion. This procedure is far simpler in 
human beings than in the dog. For the systemic perfusion 
circuit standard cardiopulmonary bypass is used with 
arterial cannulation of the ascending aorta and a single 
venous cannula placed through the right atrial appendage. 
On the pulmonary side the arterial cannula is placed 
through pursestring sutures directly into the main pulmo- 
nary artery. If the pulmonary valve is competent, no clamp 
or tourniquet isplaced proximal to the cannula, even with 
a pulmonary artery catheter in place. It is important o 
avoid pulmonary venous hypertension during lung perfu- 
sion. Therefore a large (40F) venous cannula is placed 
through the left atrial appendage. As with the single lung 
technique, a ductus is included in the tubing circuit to 
facilitate mixing of the drug. Another length of tubing is 
Table II. Lung perfusion parameters 
PA Perfusate 
Patient Perfusion Flow rate pressure temperature Time 
No. method (ml/min) (ram Hg) (°C) (rain) 
680 14 27 45 
520 17 27 45 
400 18 35 40 
2500 12 38.7 50 
2000 25 25 50 
1200 13 28.5 55 
3000 25 25 50 
2600 19 40 60 
placed between the systemic and pulmonary circuits so 
that perfusate can be easily exchanged between the cir- 
cuits while the two perfusion systems are being balanced. 
Once drug is added to the pulmonary perfusate, this line 
is clamped. 
Maintenance of constant volumes in the two perfusion 
circuits requires interruption of coronary circulation by 
aortic crossclamping. In every patient an attempt was 
made to perform lung perfusion with the heart beating 
and coronary flow intact. Invariably a large volume of 
perfusate crossed from the systemic to the pulmonary 
circuit within minutes. With the aorta crossclamped, per- 
fusate volume in the two circuits can be controlled and 
"balanced" by a few simple maneuvers. Usually the pul- 
monary circuit tends to gain volume at the expense of the 
systemic ircuit. By a combination of raising flow and perfu- 
sion pressure on the pulmonary side and reducing flow and 
pressure on the systemic side, the two circulations can be 
balanced as determined by observation of the relative per- 
fusate volume in the two reservoirs. Often, the flow rate on 
the pulmonary side exceeds the systemic flow rate. 
In this study myocardial preservation was achieved with 
cold blood cardioplegia dministered in an antegrade 
fashion through the aortic root, topical cooling with iced 
slush in the pericardium, and systemic ore cooling to 24 ° 
to 26 ° C. Myocardial temperature was carefully monitored 
with a myocardial probe in the posterior interventricular 
septum. Keeping the myocardium adequately cooled was 
sometimes problematic because the pulmonary perfusate 
returning to the left atrium was between 36 ° and 40 ° C. 
As with the canine perfusions, a left ventricular vent 
was placed through the apex of the left ventricle with 
drainage into the pulmonary reservoir. This prevented 
drug-containing perfusate from collecting in the left ven- 
tricle and potentially escaping into the aortic root and 
coronary arteries through a flaccid aortic valve. 
Lung washout. After single lung perfusion residual 
perfusate was flushed from the lung with 200 ml of 
systemic blood by releasing the left pulmonary artery 
tourniquet before clamping the venous cannula. After 
total lung perfusion the lungs were flushed with 500 to 
1000 ml of low-molecular-weight dextran before normal 
circulation was reestablished. 
Drug levels. Samples of systemic blood and pulmonary 
perfusate were taken every 10 minutes during the perfu- 
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Table III. Initial drug dose and drug levels after lung perfusion 
Patient No. 
Drug level 
Peak Peak Lymph 
Drug systemic pulmonary Lung Tumor node 
(initial dose in izg/ml ) ( txg/ml ) ( pg/ml ) ( tag/gm ) ( lag/gm ) ( Izg/gm ) 
1 Doxorubicin (1) 0.00 0.56 
2 Doxorubicin (1) 0.00 0.56 
3 Doxorubicin (1.5) 0.00 0.98 
4 Doxorubicin (3) 0.23 1.46 
5 Doxorubicin (5) 0.07 2.76 
6 Doxorubicin (10) 0.17 3.08 
7 Cisplatin (14) 0.44 9.34 
8 Cisplatin (20) 0.80 10.15 
0.72 0.64 N/A 
0.79 0.25 N/A 
2.58 0.62 N/A 
1.58 2.19 N/A 
2.13 1.56 0.01 
2.81 2.81 0.08 
0.69 1.42 0.84 
0.68 1.09 0.00 
N/A, Not applicable. 
sion and at 20 minutes after perfusion. Lung and tumor 
tissue samples were taken from representative sites with a 
stapling device immediately after perfusion. Doxorubicin 
drug levels were determined by high-pressure liquid chro- 
matography aspreviously described) Cisplatin drug levels 
were determined by digestion of solid tissue in concen- 
trated nitric acid until all organic material was broken 
down. The subsequent solution was increased to a volume 
of 10 ml with the addition of deionized water. The 
perfusate was centrifuged immediately through a centri- 
flee micropartition system to remove proteins above 
30,000 kD. Both tissue digest and ultrafiltrated perfusate 
were run on a graphite furnace atomic absorption spec- 
trophotometer and concentrations were obtained by com- 
parison with a standard line. 
Results 
All eight patients died of their disease 23 to 151 
days after lung perfusion. None had a partial or 
complete response to therapy; however, judging a 
radiographic response in patients with diffuse dis- 
ease was often impossible. There were no intraop- 
erative complications, although on occasion, cannu- 
las were repositioned for optimal perfusion and 
additional drug was added to counteract the dilu- 
tional effect of systemic blood crossing into the 
pulmonary circuit. 
Six of the eight patients were discharged from the 
hospital within 14 days after perfusion. Two major 
postoperative complications occurred. In patient 6 a 
pneumonia that responded promptly to antibiotics 
and a forceful cough productive of bits of tumor 
(confirmed by histologic study) developed. A sternal 
dehiscence developed on about he fourteenth post- 
operative day, but the rest of the wound remained 
intact and the sternal nonunion was asymptomatic. 
No subsequent therapy was required. 
Patient 7 was a 58-year-old man with diffuse 
bronchioloalveolar carcinoma (BAC), a debilitating 
cough, and decreased pulmonary function. He pre- 
viously had unsuccessful systemic doxorubicin ther- 
apy and therefore received perfusion with cisplatin. 
Four days after an uncomplicated total lung perfu- 
sion, he required reintubation and mechanical ven- 
tilation because of progressive respiratory failure. 
Respiratory function was eventually stabilized but 
multiple attempts to wean the patient from the 
respirator were unsuccessful. Pneumonia nd empy- 
ema subsequently developed and he died 81 days 
after peffusion. Postmortem examination revealed 
massive tumor involvement of the entire lung with no 
identifiable metastases to lymph nodes or distant sites. 
The chemotherapy agent used in the lung perfu- 
sion and drug levels obtained from systemic blood, 
pulmonary perfusate, lung, tumor, and lymph node 
tissue are presented in Table III. No pharmacologic 
analysis is possible with this small group of patients 
and escalating drug dosages. However, certain ob- 
servations are of interest. The amount of drug 
entering the systemic irculation was minimal, which 
indicates the high degree of lung vascular isolation 
obtained with both techniques. In the three single 
lung perfusions no drug was detected in the systemic 
circulation either during the perfusion or after the 
normal circulation was reestablished. With total 
lung perfusion some drug crossed over into the 
systemic irculation, but this averaged only about 
7% (range 2.5% to 15%) of the peak drug level in 
the pulmonary perfusate. 
Pulmonary perfusate drug levels increased appro- 
priately with increasing drug dosages. Drug tissue 
levels, although showing much more variability, also 
tended to increase with higher dosages. Mediastinal 
lymph nodes were sampled immediately after per- 
fusion in the last four patients. Three of the four 
showed etectable drug levels. In patient 6 there was 
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no discrete tumor mass within the lung; however, 
even grossly normal-appearing lung tissue showed 
diffuse histologic involvement with bronchioloalveo- 
lar carcinoma. Thus lung and tumor drug levels were 
considered identical. Significant drug levels were 
found in lung tumor specimens from every other 
patient. 
Discussion 
Once tumor within the lung is found to be unre- 
sectable, distant metastatic disease is usually 
present. Local-regional therapies are then of little 
value, except o palliate specific symptoms. There 
are, however, certain notable xceptions. BAC is an 
uncommon form of lung adenocarcinoma that often 
grows along alveolar septa without distorting the 
underlying lung parenchyma, s In its localized form, 
BAC carries the highest survival rate after surgical 
resection: up to 80% at 5 years. 9 In contrast, the 
diffuse form of the disease spreads inexorably 
throughout he lung parenchyma, often without 
evidence of systemic metastases. In advanced stages 
of BAC, patients may be incapacitated by cough 
productive of large amounts of frothy sputum. 
There is no effective treatment for this form of the 
disease. 
Surgical :resection of metastatic sarcoma to the 
lung has been one of the less-recognized achieve- 
ments in thoracic surgery. Resection has changed a
2-year survival of zero 1° to 5-year survival rates of 
40% to 50% for steosarcoma 11 nd 20% to 30% for 
soft tissue sarcoma. 12' 13 However, there are a sig- 
nificant number of patients in whom the size or 
number of metastases in the lung preclude resec- 
tion. Response to systemic hemotherapy, if any, is 
invariably transient. Most of these patients are 
young, otherwise fit, and have no other demonstra- 
ble sites of disease. 
Both BAC and sarcoma metastatic to the lung 
offer an opportunity to devise unique local-regional 
anticancer therapies. Our methods use standard 
cardiopulmonary b pass technology and equipment 
to isolate the lung from the systemic irculation. We 
then perfuse the lung with chemotherapy drugs at 
concentrations higher than those achieved by intra- 
venous administration. 
Perfusion therapy has been used for tumors of 
brain, liver, and extremities. During the early days of 
cardiac surgery attempts were made to perfuse lung 
with use of the emerging technology of cardiopul- 
monary bypass. 14-16 Our initial studies rekindled the 
concept of lung perfusion and described etailed 
methods for perfusing either one lung or both lungs 
simultaneously.i, 2 We also performed ose toxicity 
studies in rabbit and canine models for doxorubicin, 
cisplatin, and hyperthermia. 3-7Recently, Baciewicz 
and associates 17have expanded on the pharmaco- 
kinetics of doxorubicin in lung perfusion and its 
interaction with heparin. Weksler and associ- 
ateslS, 19 have devised a model of single-lung perfu- 
sion in the rat and performed studies that show 
growth inhibition of methylcholanthrene-induced 
sarcoma metastases after doxorubicin perfusion. 
Although we previously reported the pharmaco- 
kinetic data on our first three perfusion patients, 4 
this is the first study to describe in detail a series of 
patients treated with chemotherapy b isolated lung 
perfusion. This study is small and spans a number of 
years, attesting to the difficulty in convincing insti- 
tutional review boards, referring physicians, and 
prospective patients of potential merits of the pro- 
cedure. 
Theoretically, the concentration of drug exposed 
to tumor by perfusion should be considerably higher 
than that achievable by intravenous infusion. Al- 
though drug delivery by peffusion is difficult to 
compare with intravenous infusion, by calculating 
the areas under a concentration versus time curve, 
estimates of total drug delivery can be made. With 
intravenous administration there is a high initial 
peak drug level that rapidly falls off with dilution 
and a subsequent smaller peak that represents re- 
distribution. Conversely, perfusion permits delivery 
of high drug levels over a relatively short period, but 
this in theory results in considerably higher tissue 
exposure as measured by the area under the con- 
centration versus time curve. Recently Weksler and 
associates z° have shown experimentally that perfu- 
sion results in higher lung tissue levels of doxorubi- 
cin than intravenous infusion. They isolated and 
perfused rat lung at various concentrations of doxo- 
rubicin, then compared tissue levels with those 
obtained by intravenous infusion of doxorubicin at 
doses comparable to those commonly used clini- 
cally. With a perfusate drug concentration well 
tolerated by the rats, lung tissue doxorubicin levels 
were 20-fold higher than those with intravenously 
administered drug. 
A major advantage of perfusion therapy is the 
ability to isolate the lung from the systemic ircula- 
tion. Thus drugs or drug dosages too toxic to 
administer by systemic routes might safely be given 
in the lung. We have shown this to be true for 
doxorubicin, cisplatin, and hyperthermia. Except for 
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some notable pulmonary toxins, such as bleomycin, 
mitomycin, and cytoxin, many more cytotoxic agents 
may be applicable for lung perfusion. Even agents 
too toxic for systemic infusion might be tolerable if
limited to the lung. 
It was difficult to accrue patients to this study. A 
combination of its highly experimental nature and 
invasiveness tended to discourage terminally ill pa- 
tients, regardless of their physical condition. How- 
ever, the larger deterrent o both patients and 
referring oncologists eemed to be the choice of 
drugs available for perfusion. Many potential pa- 
tients already had unsuccessful systemic doxorubicin 
and cisplatin therapy. In others these drugs were not 
thought o be sufficiently active against he particu- 
lar tumor to warrant his experimental pproach. 
In addition, our preclinical aboratory studies 
were severely limited by the complexities and cost of 
performing dose-toxicity studies in our canine 
model. The model recently described by Weksler 
and Butt a8 in which lung perfusion is done in a 
tumor-bearing small animal, may allow for more 
rapid and cost-effective screening of potential 
agents. Whether tumor response in this model will 
be predictive of a similar clinical response remains 
highly speculative. 
Even though the total number of patients per- 
fused in this series is small, some preliminary obser- 
vations are of note. Most important, here was no 
major toxicity directly attributable to the lung per- 
fusion at the drug concentrations u ed. The one 
patient who died during the same hospital admission 
had the most symptoms in the group and, in retro- 
spect, was a poor candidate for the procedure. He 
had previously undergone a left lower lobectomy 
and had unsuccessful multiple chemotherapy and 
immunotherapy trials. His pulmonary function was 
markedly diminished and he required supplemental 
oxygen with exercise. At autopsy 81 days after 
perfusion the lungs were almost otally replaced by 
tumor, suggesting that his death was most likely 
related to tumor progression. Of interest, he had no 
detectable nodal or systemic metastases. 
The four patients with sarcoma tolerated perfu- 
sion exceptionally well and left the hospital between 
6 and 10 days after the procedure. Their younger 
age and better-preserved lung function make this 
group the obvious choice for future studies. Also, 
sarcoma may be more responsive to chemotherapy 
and biologic therapies than BAC. 
No patient had a demonstrable tumor response, 
either in terms of radiographic findings or survival. 
Because dose-limiting toxicity was never reached 
in this pilot study, we cannot speculate as to 
whether a clinical response might be seen at 
higher concentrations. However, both canine and 
small animal studies now suggest that much higher 
drug dosages can be achieved without untoward 
toxic effects. 1'17, 19, 21 
An often-cited criticism of lung perfusion via the 
pulmonary vasculature r lates to tumor blood sup- 
ply for lung cancers that originate primarily from the 
bronchial circulation. However, a number of exper- 
imental and autopsy studies have shown that a 
significant portion of both primary and metastatic 
tumor vasculature is fed by the pulmonary circula- 
tion.22, 23 By measuring significant levels of drug in 
tumor after isolated perfusion, our study definitively 
proves in human beings that both primary and 
metastatic cancers in the lung are at least partially 
perfused through the pulmonary circulation. 
Two methods of lung perfusion were used in 
this study, single lung perfusion and total lung 
perfusion. Single lung perfusion has the advan- 
tage of less complexity because cardiopulmonary 
bypass is not needed. Unfortunately, the tumors 
most suitable for lung perfusion invariably occur 
bilaterally, thereby requiring two separate proce- 
dures to treat the entire lung. This, and the 
observation that physiologic flow rates (and pos- 
sibly ideal drug distribution) could not be ob- 
tained in single lung perfusions without exceeding 
normal pulmonary artery pressures, led us to 
develop the total lung perfusion technique. Both 
Weksler and associates 18 and Pogrebniak and 
colleagues 24have recently described laboratory 
studies that used single lung perfusion to deliver 
experimental therapies. Perhaps early clinical 
studies hould routinely use this technique to avoid 
potentially life-threatening bilateral ung damage, 
but the ultimate clinical utility of lung perfusion will 
be best served with the total lung perfusion tech- 
nique. 
In conclusion, this highly invasive form of regional 
cancer treatment combines modern-day surgical 
techniques with anticancer therapy in an attempt to 
treat unresponsive local-regional disease. The re- 
sults of this preliminary trial are encouraging in that 
the complex procedures seem to be well tolerated 
and reproducible. Morbidity is certainly well within 
expectations for a pilot chemotherapy study. Signif- 
icant levels of drug can be measured inprimary lung 
cancer, metastatic cancer to the lung, and in the 
regional lymph nodes draining these cancers. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 2 
Johnston, Minchen, Dawson 3 7 3 
REFERENCES 
1. Johnston M, Minchin R, Shull J, et al. Isolated lung 
perfusion with Adriamycin: a preclinical study. Can- 
cer 1983;52:404-9. 
2. Johnston M, Christensen C, Minchin R, et al. Isolated 
total lung perfusion as a means to deliver organ- 
specific chemotherapy: long-term studies in animals. 
Surgery 1985;98:35-44. 
3. Minchin R, Boyd M. The uptake and metabolism of 
doxorubMn in isolated perfused rat lung. Biochem 
Pharmacol 1983;32:2829-31. 
4. Minchin R, Johnston M, Aiken M, Boyd M. Pharma- 
cokinetics of doxorubicin in isolated lung of dogs and 
humans perfused in vivo. J Pharmacol Exp Ther 
1984;229::193-8. 
5. Bongard RD, Roerig DL, Johnston MR, Linehan JH, 
Dawson CA. Influence of temperature and plasma 
protein on doxorubicin uptake by isolated lungs. Drug 
Metabol Dispos 1993;21:428-34. 
6. Rickaby D, Fehring J, Johnston M, Dawson C. Tol- 
erance of the isolated perfused lung to hyperthermia. 
J THORAC CARDIOVASC SURG 1991;101:732-9. 
7. Cowen ME, Mulvin DW, Howard RB, Dawson CA, 
Johnston MR. Lung tolerance to hyperthermia by in 
vivo perfusion. Eur J Cardiothorac Surg 1992;6:167- 
73. 
8. Marchevsky AM. Surgical pathology of lung neo- 
plasms. New York: Marcel Dekker, 1990:112. 
9. Daly R, Trastek V, Pairolero P, et al. Bronchoalveolar 
carcinoma: factors affecting survival. Ann Thorac 
Surg 1991;51:368-77. 
10. Marcove R, Martini N, Rosen G. The treatment of 
pulmonary metastasis in osteogenic sarcoma. Clin 
Orthop 1975;111:65-70. 
11. Putnam JR, Roth JA, Wesley M, Johnston MR, 
Rosenberg SA. Survival following aggressive r section 
of pulmonary metastases from osteogenic sarcoma: 
analysis of prognostic factors. Ann Thorac Surg 1983; 
35:516-23. 
12. Putnam JR, Roth JA, Wesley M, Johnston MR, 
Rosenberg SA. Analysis of prognostic factors in pa- 
tients undergoing resection of pulmonary metastases 
from soft tissue sarcomas. J THORA¢ CARDIOVASC 
SURG 1984;87:260-7. 
13. Casson A, Putnam J, Natarajan M, et al. Five-year 
survival after pulmonary metastasectomy for adult 
soft tissue sarcoma. Cancer 1992;69:662-8. 
14. Creech O Jr, Krementz E, Ryan R, Reemtsma K, 
Winblad J. Experiences with isolation-perfusion tech- 
nics in the treatment of cancer. Ann Surg 1959;149: 
627-40. 
15. Pierpont H, Blades B. Lung perfusion with chemo- 
therapeutic agents. J THORAC CARDIOVASC SURG 1960; 
39:159-65. 
16. Jacobs J, Flexner J, Scott H. Selective isolated perfu- 
sion of the right or left lung. J THORAC CARD[OVASC 
SURG 1961;42:546-52. 
17. Baciewicz F, Arredondo M, Chaudhuri B, et al. 
Pharmacokinetics and toxicity of isolated perfusion of 
lung with doxorubicin. J Surg Res 1991;50:124-8. 
18. Weksler B, Schneide A, Ng B, Burt M. Isolated single 
lung perfusion in the rat: an experimental model. 
J Appl Physiol 1993;74:2736-9. 
19. Weksler B, Lenert J, Ng B, Burt M. Isolated single 
lung perfusion with doxorubicin is effective in eradi- 
cating soft tissue sarcoma lung metastases in a rat 
model. J THORAC CARDIOVASC SURG 1994;107:50-4. 
20. Weksler B, Ng B, Lenert J, Burt M. Isolated single- 
lung perfusion with doxorubicin is pharmacokineti- 
cally superior to intravenous injection. Ann Thorac 
Surg 1993;56:209-14. 
21. Minchin R, Johnston M, Schuller J, Aiken M, Boyd 
M. Pulmonary toxicity of doxorubicin administered by 
in situ isolated lung perfusion in dogs. Cancer 1988; 
61:1320-5. 
22. Cudkowicz C, Armstrong J. The blood supply of malig- 
nant pulmonary neoplasms. Thorax Lung 1951;8:152-6. 
23. Miller B, Rosenbaum A. The vascular supply to 
metastatic tumors of the lung. Surg Gynecol Obstet 
1967;125:1009-16. 
24. Pogrebniak H, Witt C, Terrill R, et al. Isolated lung 
perfusion with tumor necrosis factor: a swine model in 
preparation of human trials. Ann Thorac Surg 1994; 
57:1477-83. 
